CA2577191A1 - Derives de phtalazinone substitues par un groupe 4-heteroarylmethyle - Google Patents
Derives de phtalazinone substitues par un groupe 4-heteroarylmethyle Download PDFInfo
- Publication number
- CA2577191A1 CA2577191A1 CA002577191A CA2577191A CA2577191A1 CA 2577191 A1 CA2577191 A1 CA 2577191A1 CA 002577191 A CA002577191 A CA 002577191A CA 2577191 A CA2577191 A CA 2577191A CA 2577191 A1 CA2577191 A1 CA 2577191A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- group
- compound
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0419072.4A GB0419072D0 (en) | 2004-08-26 | 2004-08-26 | Phthalazinone derivatives |
| GB0419072.4 | 2004-08-26 | ||
| US60495604P | 2004-08-27 | 2004-08-27 | |
| US60/604,956 | 2004-08-27 | ||
| PCT/GB2005/003343 WO2006021801A1 (fr) | 2004-08-26 | 2005-08-26 | Derives de phtalazinone substitues par un groupe 4-heteroarylmethyle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2577191A1 true CA2577191A1 (fr) | 2006-03-02 |
Family
ID=35219560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002577191A Abandoned CA2577191A1 (fr) | 2004-08-26 | 2005-08-26 | Derives de phtalazinone substitues par un groupe 4-heteroarylmethyle |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1791827A1 (fr) |
| JP (1) | JP2008510783A (fr) |
| KR (1) | KR20070057859A (fr) |
| AU (1) | AU2005276229A1 (fr) |
| BR (1) | BRPI0514632A (fr) |
| CA (1) | CA2577191A1 (fr) |
| IL (1) | IL181408A0 (fr) |
| MX (1) | MX2007002318A (fr) |
| NO (1) | NO20071579L (fr) |
| NZ (1) | NZ553979A (fr) |
| WO (1) | WO2006021801A1 (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| CA2652167A1 (fr) | 2006-05-31 | 2007-12-06 | Philip Jones | Derives de pyrrolo[1,2-a]pyrazin-1(2h)-one et de pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one utilises en tant qu'inhibiteurs de la poly(adp-ribose)polymerase (parp) |
| KR101591656B1 (ko) | 2007-01-10 | 2016-02-19 | 엠에스디 이탈리아 에스.알.엘. | 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸 |
| JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体拮抗薬およびその使用 |
| GB0716532D0 (en) | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| MX2010002749A (es) * | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
| JP5758630B2 (ja) | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 |
| UY31603A1 (es) * | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| BRPI0923051B1 (pt) * | 2008-12-19 | 2022-07-19 | Centrexion Therapeutics Corporation | Pirimidin-4-carboxamidas cíclicas como antagonistas do receptor de ccr2 para o tratamento de inflamação, asma e copd, seu uso, formulação e combinação farmacêutica que os compreende |
| PT2513093E (pt) | 2009-12-17 | 2014-10-22 | Boehringer Ingelheim Int | Novos antagonistas do receptor ccr2 e suas utilizações |
| JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
| EP2569298B1 (fr) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Nouveaux antagonistes du récepteur ccr2, son procédé de production et utilisation associée en tant que médicaments |
| JP5647339B2 (ja) | 2010-05-17 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２アンタゴニスト及びこれらの使用 |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| JP2013532683A (ja) | 2010-07-27 | 2013-08-19 | カディラ ヘルスケア リミティド | ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体 |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| KR101242572B1 (ko) * | 2010-10-12 | 2013-03-19 | 한국화학연구원 | 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물 |
| US8999985B2 (en) * | 2010-12-02 | 2015-04-07 | Shanghai De Novo Pharmatech Co Ltd. | Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof |
| CN103443085B (zh) * | 2011-03-14 | 2016-03-23 | 南京英派药业有限公司 | 喹唑啉二酮及其应用 |
| CN103717609B (zh) * | 2011-05-31 | 2016-05-11 | 江苏康缘药业股份有限公司 | 聚(adp-核糖)聚合酶的三环抑制剂 |
| WO2013010839A1 (fr) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Antagonistes de ccr2 nouveaux et sélectifs |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102964354B (zh) * | 2012-11-16 | 2014-08-13 | 江苏先声药业有限公司 | 一类噻吩并咪唑衍生物及其应用 |
| CN102977040B (zh) * | 2012-11-20 | 2015-06-03 | 浙江工业大学 | 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法 |
| HUE030613T2 (en) | 2012-12-31 | 2017-05-29 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
| RU2737434C2 (ru) | 2013-03-13 | 2020-11-30 | Форма Терапьютикс, Инк. | Новые соединения и композиции для ингибирования fasn |
| CN106146492A (zh) * | 2015-04-17 | 2016-11-23 | 上海汇伦生命科技有限公司 | 杂环并咪唑类化合物、其药物组合物及其制备方法和用途 |
| PL3317270T3 (pl) | 2015-07-02 | 2020-11-16 | Centrexion Therapeutics Corporation | Cytrynian (4-((3r,4r)-3-metoksytetrahydropiran-4-yloamino)piperydyn-1-ylo)(5-metylo-6-(((2r,6s)-6-(p-tolilo)tetrahydro-2h-piran-2-ylo)metylamino)pirymidyn-4-ylo)metanonu |
| CN105384684B (zh) * | 2015-12-16 | 2018-02-13 | 辽宁工程技术大学 | 一种2‑氰基‑6‑甲基吡啶的制备方法 |
| US11542282B2 (en) | 2018-02-28 | 2023-01-03 | The Trustees Of The University Of Pennsylvania | Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| EP3873214A4 (fr) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | Formes solides de (4-(2-fluoro-4-(1-méthyl-1h-benzo[d]imidazol-5-yl)benzoyl)pipérazin-1-yl)(1-hydroxycyclopropyl)méthanone |
| WO2020155141A1 (fr) * | 2019-02-02 | 2020-08-06 | 中国科学院上海有机化学研究所 | Composition pharmaceutique de traitement de maladies neurodégénératives ou de maladies provoquées par l'anomalie d'une protéine de liaison à l'arn et ses applications |
| EP3999506A1 (fr) | 2019-07-19 | 2022-05-25 | Astrazeneca AB | Inhibiteurs de parp1 |
| KR20230002487A (ko) | 2020-04-28 | 2023-01-05 | 리젠 파마슈티컬스 아게 | 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물 |
| WO2022090938A1 (fr) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Dérivés de phtalazinone utiles en tant qu'inhibiteurs de parp |
| CA3214298A1 (fr) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibiteurs de la poly(adp-ribose) polymerase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA882639B (en) * | 1987-05-02 | 1988-09-30 | Asta-Pharma Aktiengesellschaft | New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives |
| DE3813531A1 (de) * | 1987-05-02 | 1988-11-10 | Asta Pharma Ag | Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate |
| CN1136197C (zh) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
| GB0026505D0 (en) * | 2000-10-30 | 2000-12-13 | Kudos Pharm Ltd | Phthalazinone derivatives |
| EA006300B1 (ru) * | 2000-10-30 | 2005-10-27 | Кудос Фармасеутикалс Лимитед | Производные фталазинона |
| US6664269B2 (en) * | 2001-05-08 | 2003-12-16 | Maybridge Plc | Isoquinolinone derivatives |
| NZ534712A (en) * | 2002-02-19 | 2006-11-30 | Ono Pharmaceutical Co | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| US7196085B2 (en) * | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| CA2517629C (fr) * | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Derives de phtalazinone |
-
2005
- 2005-08-26 CA CA002577191A patent/CA2577191A1/fr not_active Abandoned
- 2005-08-26 KR KR1020077006778A patent/KR20070057859A/ko not_active Application Discontinuation
- 2005-08-26 AU AU2005276229A patent/AU2005276229A1/en not_active Abandoned
- 2005-08-26 NZ NZ553979A patent/NZ553979A/en not_active IP Right Cessation
- 2005-08-26 MX MX2007002318A patent/MX2007002318A/es active IP Right Grant
- 2005-08-26 BR BRPI0514632-1A patent/BRPI0514632A/pt not_active IP Right Cessation
- 2005-08-26 JP JP2007528985A patent/JP2008510783A/ja active Pending
- 2005-08-26 WO PCT/GB2005/003343 patent/WO2006021801A1/fr active Application Filing
- 2005-08-26 EP EP05775527A patent/EP1791827A1/fr not_active Withdrawn
-
2007
- 2007-02-18 IL IL181408A patent/IL181408A0/en unknown
- 2007-03-26 NO NO20071579A patent/NO20071579L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006021801A1 (fr) | 2006-03-02 |
| KR20070057859A (ko) | 2007-06-07 |
| JP2008510783A (ja) | 2008-04-10 |
| NZ553979A (en) | 2009-05-31 |
| IL181408A0 (en) | 2007-07-04 |
| AU2005276229A1 (en) | 2006-03-02 |
| EP1791827A1 (fr) | 2007-06-06 |
| BRPI0514632A (pt) | 2008-06-17 |
| NO20071579L (no) | 2007-05-29 |
| MX2007002318A (es) | 2007-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7407957B2 (en) | Phthalazinone derivatives | |
| US11160803B2 (en) | Phthalazinone derivatives | |
| CA2577191A1 (fr) | Derives de phtalazinone substitues par un groupe 4-heteroarylmethyle | |
| CA2517629C (fr) | Derives de phtalazinone | |
| US7470688B2 (en) | Phthalazinone derivatives | |
| EP1828118A1 (fr) | Inhibiteurs de parp | |
| CA2683682A1 (fr) | Derives de phthalazinone et leur utilisation en tant que medicaments destines a traiter le cancer | |
| CA2691459A1 (fr) | Derives de phtalazinone comme inhibiteurs de parp-1 | |
| US20080280910A1 (en) | Phthalazinone derivatives | |
| CA2699038A1 (fr) | Derives de phtalazinone | |
| US20230015617A1 (en) | Phthalazinone derivatives | |
| MX2008004913A (en) | 4-heteroarymethyl substituted phthalazinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |